I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 021706-000810US

Assistant Commissioner for Patents

Washington, D.C. 20231

on May 17, 2004

TOWNSEND and TOWNSEND and CREW LLP

By: Sylva Edmold

OLD 2 4 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Tony Wai-Chiu So et al.

Application No.: 10/124,197

Filed: April 16, 2002

For: PHARMACEUTICAL

COMPOSITION

Customer No.: 20350

Confirmation No. 1659

Examiner:

Sharmila S. Gollamudi

Technology Center/Art Unit: 1616

DECLARATION UNDER 37 C.F.R. § 1.132

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

- I, Albert Zorko Abram, being duly warned that willful false statements and the like are punishable by fine or imprisonment or both, under 18 U.S.C. § 1001, and may jeopardize the validity of the patent application or any patent issuing thereon, state and declare as follows:
- 1. All statements herein made of my own knowledge are true and statements made on information or belief are believed to be true.
- 2. I am currently employed by Connetics Australia Pty Ltd, the assignee of the subject application.
- 3. I am a Senior Chemist Technical IP Associate and have been in pharmaceutical research since 1987. I have been employed doing dermatological product development for the last 16 years. My Curriculum Vitae is of record.

PATENT

Tony Wai-Chiu So et al. Application No.: 10/124,197 Page 2

- 4. I have reviewed and analyzed the above-referenced patent application, and I am familiar with the contents therein.
- 5. It is my understanding that the Examiner alleges in the Office Action dated October 17, 2003 that, in the Declaration under 37 C.F.R. § 1.132 submitted on April 1, 2003 ("the 2003 Declaration"), Applicants did not provide the identity and amount of the components in the inventive foam formulation used for the side-by-side comparison with the foam formulation of Di Schiena (U.S. Patent No. 4,866,067). For the reasons set forth herein, the Examiner's concerns are overcome.
- 6. As described in the 2003 Declaration, the formulation set forth in column 3, Example 3(e) of Di Schiena, entitled "Foam," was prepared in our laboratory at Connetics Australia following the teaching of Di Schiena with an understanding of the foam art.
- 7. Exhibit A contains a true copy of a page from a Connetics' laboratory notebook, with the date redacted therefrom. As shown in Exhibit A, the Di Schiena foam ("comparative") was prepared according to the teaching set forth in Example 3(e) of Di Schiena. An accepted hydrocarbon propellant (i.e., Propellant P70) was substituted for the chlorofluorocarbon propellant of Di Schiena at an amount to produce a foam of acceptable quality (see, the 2003 Declaration).
- 8. The foam as disclosed in the subject application ("inventive") was prepared in our laboratory according to the following formulation:

Component	% w/w
Minoxidil	4.75
Ethanol	53.645
Purified Water	31.410
Butylated Hydroxytoluene	0.095
Lactic Acid (90%)	1.00
Citric Acid	0.10
Stearyl Alcohol	0.50
Cetyl Alcohol	1.10
Polysorbate 60	0.40
Propylene Glycol	2.00
Propellant P70	5.00
Total	100.00

- 9. Exhibit B contains a true copy of a page from my notebook, with the date redacted therefrom, disclosing the formulation set forth in the table above.
- 10. As described in the 2003 Declaration, I have performed a side-by-side comparison of the inventive foam against the comparative foam and found unexpected properties in the

Tony Wai-Chiu So et al. Application No.: 10/124,197 Page 3

PATENT

inventive foam that were not present in the comparative foam, including foam consistency, stability, and advantageous mechanical shear properties.

The declarant has nothing further to say.

Albert Zorko Abram

60195896 v1



43 Experient: 187/1... Ologos a sangle of the Di Shien Someth 91117 Nicothic - Acid - N-Oril . 11065 O Corplan shoot 21245 There D ho were misel at our temperate and formated found a thin latin ford.

at an added the thin get / latin getted

oring a laminat surfactment thaten not

70% SLES. Would this happen with popular

CH Innovation in Drug Delivery

Manufacturing Dossier Strictly confidential

Softec Item description: 5.
Softec Formula: F1.
Softec Batch Number: F1.

5% Minoxidil Mousse F112/29/03 E126/10/01

Batch Record

		٠.	h(L	1000	•	9			¥	Á	6	8	8	7	6	0		4	ü	2		·	
	سإ		1			1				4		L	L	Ŀ		Ĺ	L	Ŀ	<u>.</u>			L	
		₩#We YL 33383 <	St x 125mm				77.50	170 tabliant P70	3 988	hppylene Glycol	Lactic Acid (80%)	Minoxidil	Citric acid	Purified Water	Butylated hydroxytoluene	Ethanol 100AG22	Phase 2	Cetyl alcohol	Stearyl alcohol	Polysorbate 60	Ethanol 100AG 22	Phase 1	
		2	원 공									·											n vena
7		N.)				L7707	222		2727	2721	20105	21369	6-Jan -02	21368	100cc		29816	1951	2/371	7004		100
		•	-			100.00	5.00		2.00	200	1.00	4.75	0.10	31.410	0.085	43.645		1 10	0.50	0.40	10.00	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
						5,000.00	250.00		100.00	100.00	3	237.50	500	1570.50	4.75	2182 25	00:00	22.00	25.00	20.00	303		
								4.5917	0.001	477	6.00	20.0	2007	1583.3	200.4	2,000.0	100.0	300	4)	10.00	600.0		· · · · · · · · · · · · · · · · · · ·
									*	1	1	N.	1	1		K	P	8	1	1	1		
				Com rest of 1	ľ			language 1			ward war	Keother top		-	t	EX		1	(G store	+ themships	Reader love		
				, C. (Rose	クリフト		- euoo-	المعادد	5 60 .00	はい	47.5914: Nasasa	Dec. 100:26	7	K876.8	8 63 63 .	Extra Cook		876.	100	0.00	18-21		